Teva, US Agree to $450 Million Settlement in Kickback Case (1)

Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. will pay $450 million to resolve claims that they violated the False Claims Act by engaging in kickback schemes, the Justice Department said Thursday.

The settlement resolves allegations that Teva paid Medicare patients’ cost sharing obligations for multiple sclerosis drug Copaxone while steadily raising the drug’s price, the announcement said.

Teva USA also agreed to resolve separate allegations that it conspired with other generic drug manufacturers to fix prices for pravastatin, a drug used to treat cholesterol and triglyceride levels, as well as two other generic drugs, the announcement said.

“Teva ...